Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Gebra Cuyun Carter"'
Autor:
Alison Davie, Gebra Cuyun Carter, Alex Rider, James Pike, Katie Lewis, Abigail Bailey, Gregory L. Price, Francois Ringeisen, Xavier Pivot
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-15 (2020)
Abstract Background Endocrine therapy (ET)-based regimens are the mainstay of treatment for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer. With the introduction of new t
Externí odkaz:
https://doaj.org/article/7fe4847e3d934667a90f1ffc58d8e438
Publikováno v:
Health and Quality of Life Outcomes, Vol 18, Iss 1, Pp 1-14 (2020)
Abstract Background To compare quality of life of patients treated with cetuximab with or without radiation therapy (±RT) vs. cisplatin±RT for locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) in the real-world setting. M
Externí odkaz:
https://doaj.org/article/4bbdccb926eb4645b3e424e7271cf9c2
Autor:
Adrian D. Vickers, Katherine B. Winfree, Gebra Cuyun Carter, Urpo Kiiskinen, Min-Hua Jen, Donald Stull, James A. Kaye, David P. Carbone
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-16 (2019)
Abstract Background Locally advanced or metastatic non-small cell lung cancer (NSCLC) that has progressed after first-line treatment has a poor prognosis. Recent randomized clinical trials (RCTs) have demonstrated survival benefits of alternative tre
Externí odkaz:
https://doaj.org/article/372369967d9c4a9cb9d9327001d909f8
Autor:
Rebecca Ellen Goulding, Matthew Chenoweth, Gebra Cuyun Carter, Mark Ernest Boye, Kristin M Sheffield, William J John, Mark Steven Leusch, Catherine Elizabeth Muehlenbein, Li Li, Min-Hua Jen, Adina Rojubally, Jeroen Jansen, Eric Druyts
Publikováno v:
Cancer Treatment and Research Communications, Vol 24, Iss , Pp 100200- (2020)
KRAS (Kirsten Rat Sarcoma) is the most common oncogenic mutation detected in patients with non-small cell lung cancer (NSCLC). However, the role of KRAS as either a prognostic factor or predictive factor (modifier of treatment effects) in NSCLC is no
Externí odkaz:
https://doaj.org/article/8d4a2489397e4e478a6287ecb9ffb2ec
Autor:
Vladislav Berdunov, Gebra Cuyun Carter, Ewan Laws, Roger Luo, Christy Russell, Sara Campbell, Yara Abdou, Jeremy Force
Publikováno v:
Journal of the National Comprehensive Cancer Network. 20:HSR22-129
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4117543f862a84c4d6f71bc1a1580aed
https://doi.org/10.6004/jnccn.2021.7241
https://doi.org/10.6004/jnccn.2021.7241
Autor:
Yajun Emily Zhu, Yu-Jing Huang, Andrew D. Seidman, Claudia Morato Guimaraes, Gebra Cuyun Carter, Kristin M Sheffield, Anala Gossai, Erik Rasmussen, Shreya Balakrishna, Emily Nash Smyth, Sarah Rybowski, Aaron B Cohen, Raina Mathur, Lee Bowman
Publikováno v:
Current Medical Research and Opinion. 37:1179-1187
This retrospective observational study described baseline characteristics, real-world treatment patterns, and outcomes among patients with metastatic breast cancer treated with abemaciclib in the United States.De-identified electronic health record-d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c658f1fd567ad835f04c4e9760d53c4f
https://doi.org/10.1080/03007995.2021.1923468
https://doi.org/10.1080/03007995.2021.1923468
Autor:
Yajun Emily Zhu, Lisa M. Hess, Suvapun Bunniran, Cliff Molife, Gebra Cuyun Carter, Yihua Xu, Sheetal Sheth, Radhika Nair
Publikováno v:
The American Journal of Managed Care. 27:e105-e113
OBJECTIVES To compare treatments, overall survival (OS), and total costs among patients receiving anticancer therapy in hospital outpatient vs physician office settings. STUDY DESIGN This retrospective observational study utilized claims data from a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a3179096f27769b3cf44bb29ea9ee66
https://doi.org/10.37765/ajmc.2021.88619
https://doi.org/10.37765/ajmc.2021.88619
Autor:
Paula D. Ryan, Yu-Jing Huang, Kristin M Sheffield, Gebra Cuyun Carter, Jonathan Rajkumar, Lavanya Sudharshan, Gregory L Price, Claudia Morato Guimaraes, Emily Nash Smyth, Sarah Rybowski
Publikováno v:
Journal of the National Comprehensive Cancer Network. 19:HSR21-051
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aaaec05c52b133dd6b916c6841e163bd
https://doi.org/10.6004/jnccn.2020.7739
https://doi.org/10.6004/jnccn.2020.7739
Autor:
Xiaohong I Li, Maura N. Dickler, Hans Wildiers, Martin Frenzel, Yu-Jing Huang, Sara M. Tolaney, Debra A. Patt, Véronique Diéras, Esther Zamora, Joyce O'Shaughnessy, Kristin M Sheffield, Valerie Andre, Li Li, Gebra Cuyun Carter, Javier Cortes, Denise A. Yardley, Hope S. Rugo
Publikováno v:
Breast Cancer Research and Treatment
Scientia
Scientia
Purpose In MONARCH 1 (NCT02102490), single-agent abemaciclib demonstrated promising efficacy activity and tolerability in a population of heavily pretreated women with refractory HR+, HER2− metastatic breast cancer (MBC). To help interpret these re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e5720af297b83601c722500f00f7dfe
https://doi.org/10.1007/s10549-020-05838-5
https://doi.org/10.1007/s10549-020-05838-5
Autor:
Keri Stenger, Sheena Singh, Sherko Kümmel, Sara M. Tolaney, Amy Lee Chong, Vanita Tongbram, Pradeep Basa, Valentina Guarneri, Gebra Cuyun Carter, Shivaprasad Singuru, Maitreyee Mohanty
Publikováno v:
Cancer Research. 80:P3-08
Background Advanced breast cancer (ABC) is a heterogeneous disease with several well-defined subtypes, among which, HR+, HER2- is the most prevalent. While clinical factors and genomic signatures have clear prognostic significance in the early breast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b928727674a1ad59117593ae31213a17
https://doi.org/10.1158/1538-7445.sabcs19-p3-08-40
https://doi.org/10.1158/1538-7445.sabcs19-p3-08-40